|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16/09/14 | CHUGAI PHARMACEUTICAL : Roche's $8 billion InterMune buy not a signal for more big deals | RE |
| 04/09/14 | Roche : rules out mega deals, open to smaller ones - paper | RE |
Executive Committee: InterMune Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Thompson
CEO | Chief Executive Officer | 57 | - |
| Chief Tech/Sci/R&D Officer | 71 | 31/03/2002 | |
Carla Fiankan
LAW | General Counsel | - | 31/07/2011 |
Company details: InterMune Inc
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.64% | +7.07% | +11.87% | +38.40% | 47.97B | |
| +0.22% | +0.40% | +49.94% | +37.06% | 44.5B | |
| -1.58% | +4.66% | +337.90% | +614.38% | 43.93B | |
| +1.70% | +0.36% | +10.27% | +99.27% | 41.03B | |
| +0.51% | -0.61% | +5.18% | +46.87% | 29.85B | |
| -0.48% | -1.32% | +23.00% | +150.01% | 17.27B | |
| +0.08% | +9.03% | +8.29% | - | 15.34B | |
| +1.76% | +2.98% | +29.13% | +45.78% | 15.3B | |
| +1.97% | -3.17% | - | - | 14.82B | |
| Average | +0.68% | +2.46% | +59.45% | +147.39% | 30B | |
| Weighted average by Cap. | +0.68% | +2.97% | +75.17% | +163.62% |
- Stock Market
- Stocks
- Stock
- Company InterMune Inc
Select your edition
All financial news and data tailored to specific country editions
